Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia.
Journal
The Lancet. Respiratory medicine
ISSN: 2213-2619
Titre abrégé: Lancet Respir Med
Pays: England
ID NLM: 101605555
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
21
11
2018
revised:
06
03
2019
accepted:
08
03
2019
pubmed:
12
6
2019
medline:
3
7
2020
entrez:
12
6
2019
Statut:
ppublish
Résumé
Hospital-acquired pneumonia is a major cause of morbidity and mortality. The incidence of hospital-acquired pneumonia remains high globally and treatment can often be ineffective. Here, we review the available data and unanswered questions surrounding hospital-acquired pneumonia, discuss alterations of the respiratory microbiome and of the mucosal immunity in patients admitted to hospital, and explore potential approaches to stratify patients for tailored treatments. The lungs have been considered a sterile organ for decades because microbiological culture techniques had shown negative results. Culture-independent techniques have shown that healthy lungs harbour a diverse and dynamic ecosystem of bacteria, changing our comprehension of respiratory physiopathology. Understanding dysbiosis of the respiratory microbiome and altered mucosal immunity in patients with critical illness holds great promise to develop targeted host-directed immunotherapy to reduce ineffective treatment, to improve patient outcomes, and to tackle the global threat of resistant bacteria that cause these infections.
Identifiants
pubmed: 31182406
pii: S2213-2600(19)30140-7
doi: 10.1016/S2213-2600(19)30140-7
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-720Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.